Ascentage Pharma receives $100m payment from Takeda under exclusive option agreement
Ascentage Pharma, a leading global biopharmaceutical company specializing in novel therapies for cancer and other serious diseases, has announced the receipt of a US$100 million option payment from Takeda. This payment is part of an Exclusive Option Agreement that grants Takeda the opportunity to license the potentially groundbreaking BCR-ABL inhibitor, olverembatinib. – Substantial Financial Commitment: […]
